Do analysts recommend NTRB or INGN?

Inogen has a consensus price target of $14.00, indicating a potential upside of 134.11%. Given Inogen's stronger consensus rating and higher possible upside, analysts clearly believe Inogen is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Inogen 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, NTRB or INGN?

Nutriband has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 20.60 -$8.23M -$2.60 N/A Inogen $348.67M 0.46 -$22.75M -$0.91 N/A

Is NTRB or INGN more profitable?

Inogen has a net margin of -7.08% compared to Nutriband's net margin of -403.98%. Inogen's return on equity of -12.90% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -403.98% -118.33% -101.92% Inogen -7.08% -12.90% -8.27%

Do analysts prefer NTRB or APYX?

Apyx Medical has a consensus target price of $6.50, indicating a potential upside of 71.50%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Apyx Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is NTRB or APYX more profitable?

Apyx Medical has a net margin of -16.40% compared to Nutriband's net margin of -403.98%. Apyx Medical's return on equity of -88.47% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -403.98% -118.33% -101.92% Apyx Medical -16.40% -88.47% -14.94%

Do analysts prefer NTRB or CVRX?

CVRx has a consensus price target of $11.50, indicating a potential upside of 113.36%. Given CVRx's stronger consensus rating and higher possible upside, analysts plainly believe CVRx is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CVRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, NTRB or CVRX?

Nutriband has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 20.60 -$8.23M -$2.60 N/A CVRx $56.65M 2.53 -$53.31M -$2.02 N/A

Is NTRB or CVRX more profitable?

CVRx has a net margin of -89.14% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -403.98% -118.33% -101.92% CVRx -89.14% -120.76% -48.38%

Do analysts prefer NTRB or ?

Given 's higher probable upside, analysts clearly believe is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, NTRB or ?

has lower revenue, but higher earnings than Nutriband. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 20.60 -$8.23M -$2.60 N/A N/A N/A N/A N/A N/A

Is NTRB or more profitable?

has a net margin of 0.00% compared to Nutriband's net margin of -403.98%. 's return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -403.98% -118.33% -101.92% N/A N/A N/A

Do analysts recommend HYPR or NTRB?

Hyperfine currently has a consensus price target of $1.78, indicating a potential upside of 19.69%. Given Hyperfine's stronger consensus rating and higher possible upside, research analysts plainly believe Hyperfine is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperfine 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is HYPR or NTRB more profitable?

Hyperfine has a net margin of -226.88% compared to Nutriband's net margin of -403.98%. Hyperfine's return on equity of -98.83% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% Nutriband -403.98% -118.33% -101.92%

Nutriband (NTRB) Competitors

$3.46 -0.09 (-2.65%)

Closing price 03:57 PM Eastern

Extended Trading

$3.50 +0.04 (+1.27%)

As of 06:54 PM Eastern

Compare

NTRB vs. INGN, APYX, CVRX, EDAP, and HYPR

Should you buy Nutriband stock or one of its competitors? MarketBeat compares Nutriband with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nutriband include Inogen (INGN), Apyx Medical (APYX), CVRx (CVRX), Edap Tms (EDAP), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry.

How does Nutriband compare to Inogen?

Nutriband (NASDAQ:NTRB) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Inogen has a consensus price target of $14.00, indicating a potential upside of 134.11%. Given Inogen's stronger consensus rating and higher possible upside, analysts clearly believe Inogen is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Nutriband has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Inogen has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Inogen has a net margin of -7.08% compared to Nutriband's net margin of -403.98%. Inogen's return on equity of -12.90% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Inogen	-7.08%	-12.90%	-8.27%

19.7% of Nutriband shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nutriband has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	20.60	-$8.23M	-$2.60	N/A
Inogen	$348.67M	0.46	-$22.75M	-$0.91	N/A

In the previous week, Inogen had 3 more articles in the media than Nutriband. MarketBeat recorded 4 mentions for Inogen and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.93 beat Inogen's score of 0.43 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Positive
Inogen	Neutral

Summary

Inogen beats Nutriband on 11 of the 17 factors compared between the two stocks.

How does Nutriband compare to Apyx Medical?

Nutriband (NASDAQ:NTRB) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Nutriband has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Apyx Medical has a net margin of -16.40% compared to Nutriband's net margin of -403.98%. Apyx Medical's return on equity of -88.47% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
Apyx Medical	-16.40%	-88.47%	-14.94%

Nutriband has higher earnings, but lower revenue than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	20.60	-$8.23M	-$2.60	N/A
Apyx Medical	$52.84M	3.00	-$11.21M	-$0.22	N/A

19.7% of Nutriband shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 15.2% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Apyx Medical has a consensus target price of $6.50, indicating a potential upside of 71.50%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Apyx Medical had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Apyx Medical and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.93 beat Apyx Medical's score of 0.54 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Positive
Apyx Medical	Positive

Summary

Apyx Medical beats Nutriband on 11 of the 17 factors compared between the two stocks.

How does Nutriband compare to CVRx?

Nutriband (NASDAQ:NTRB) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

CVRx has a net margin of -89.14% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
CVRx	-89.14%	-120.76%	-48.38%

19.7% of Nutriband shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 13.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CVRx has a consensus price target of $11.50, indicating a potential upside of 113.36%. Given CVRx's stronger consensus rating and higher possible upside, analysts plainly believe CVRx is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

Nutriband has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, CVRx has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Nutriband has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	20.60	-$8.23M	-$2.60	N/A
CVRx	$56.65M	2.53	-$53.31M	-$2.02	N/A

In the previous week, CVRx had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for CVRx and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.93 equaled CVRx'saverage media sentiment score.

Company	Overall Sentiment
Nutriband	Positive
CVRx	Positive

Summary

CVRx beats Nutriband on 10 of the 16 factors compared between the two stocks.

How does Nutriband compare to ?

Nutriband (NASDAQ:NTRB) and (:) are related companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, had 1393 more articles in the media than Nutriband. MarketBeat recorded 1394 mentions for and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.93 beat 's score of 0.00 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Positive
	Neutral

19.7% of Nutriband shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Given 's higher probable upside, analysts clearly believe is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

has a net margin of 0.00% compared to Nutriband's net margin of -403.98%. 's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-403.98%	-118.33%	-101.92%
	N/A	N/A	N/A

has lower revenue, but higher earnings than Nutriband.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	20.60	-$8.23M	-$2.60	N/A
	N/A	N/A	N/A	N/A	N/A

Summary

Nutriband and tied by winning 5 of the 10 factors compared between the two stocks.

How does Nutriband compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Hyperfine has a net margin of -226.88% compared to Nutriband's net margin of -403.98%. Hyperfine's return on equity of -98.83% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Nutriband	-403.98%	-118.33%	-101.92%

In the previous week, Hyperfine had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Hyperfine and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.93 beat Hyperfine's score of -0.03 indicating that Nutriband is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperfine	Neutral
Nutriband	Positive

Hyperfine currently has a consensus price target of $1.78, indicating a potential upside of 19.69%. Given Hyperfine's stronger consensus rating and higher possible upside, research analysts plainly believe Hyperfine is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Hyperfine has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nutriband has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.97	-$35.57M	-$0.41	N/A
Nutriband	$2.04M	20.60	-$8.23M	-$2.60	N/A

Summary

Hyperfine beats Nutriband on 9 of the 16 factors compared between the two stocks.

Get Nutriband News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRB vs. The Competition

Export

Metric	Nutriband	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.15M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-1.33	17.69	22.39	24.18
Price / Sales	20.60	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	6.28	3.85	9.84	6.72
Net Income	-$8.23M	$75.85M	$3.57B	$337.19M
7 Day Performance	1.65%	-1.67%	-1.16%	0.48%
1 Month Performance	-10.47%	22.18%	3.85%	5.07%
1 Year Performance	-55.18%	21.83%	27.40%	34.25%

Nutriband Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRB Nutriband	0.6909 of 5 stars	$3.46 -2.6%	N/A	-56.2%	$43.15M	$2.04M	N/A	10	Gap Down
INGN Inogen	3.9459 of 5 stars	$6.58 +2.8%	$14.00 +112.8%	-4.2%	$173.28M	$348.67M	N/A	1,030
APYX Apyx Medical	3.037 of 5 stars	$4.09 -1.0%	$6.50 +58.9%	+137.7%	$172.94M	$52.84M	N/A	270
CVRX CVRx	2.6151 of 5 stars	$6.08 -0.5%	$11.50 +89.1%	-16.2%	$162.13M	$56.65M	N/A	160
EDAP Edap Tms	N/A	$4.31 +0.2%	$6.00 +39.2%	N/A	$161.17M	$70.53M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRB) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutriband (NTRB) Competitors